摘要
目的 探讨放射性125I粒子植入联合西妥昔单克隆抗体治疗直肠癌术后复发患者的近期疗效.方法 纳入2014年7月至2018年6月在山东省医学科学院附属医院就诊的57例直肠癌术后复发患者,根据治疗方法分成仅采用放射性125I粒子治疗的放射治疗组(30例)与采用放射性125I粒子联合西妥昔单克隆抗体治疗的联合治疗组(27例).观察两组患者的肿瘤变化、疼痛缓解和不良反应发生情况等.统计学方法采用卡方检验.结果 术后6个月,联合治疗组患者的总有效率和局部控制率分别为54.2% (13/24)和87.5%(21/24),分别高于放射治疗组的17.9%(5/28)和39.3%(11/28),差异均有统计学意义(x2=15.01、2.55,P均<0.05).术后1个月,放射治疗组与联合治疗组的疼痛缓解率分别为70.0%(21/30)和85.2%(23/27),差异无统计学意义(P>0.05).术后6个月,放射治疗组与联合治疗组的不良反应发生率分别为46.7% (14/30)和63.0%(17/27),差异无统计学意义(P>0.05).放射性损伤患者给予对症处理后,其症状明显好转.结论 放射性125I粒子植入联合西妥昔单克隆抗体治疗直肠癌术后复发患者的近期疗效优于单纯采用放射性125I粒子植入治疗患者.
Objective To evaluate the short-term efficacy of combination of 125 I seed brachytherapy and cetuximab in postoperation recurrent rectum cancer.Methods From July 2014 to June 2018,at Affiliated Hospital of Shandong Academy of Medical Sciences,57 patients with postoperation recurrent rectal cancer were recruited.According to therapy the patients were divided into two groups:the radiotherapy group(30 cases)treated with radioactive 125I seeds alone and the combination treatment group(27 cases)treated with combination of radioactive 125I seeds and cetuximab.The tumor size,pain relief and adverse reactions were observed in both groups.Chi-square test were performed for statistical analysis.Results After treatment for six months,the total efficacy rate and local control rate of combination treatment group were 54.2%(13/24)and 87.5%(21/24),respectively;and which were higher than those of radiotherapy group(17.9%,5/28 and 39.3%,11/28),and the differences were statistically significant(x2=15.01 and 2.55,both P<0.05).At one month after treatment,the pain relief rate of radiotherapy group and combination treatment group was 70.0%(21/30)and 85.2%(23/27),respectively,and there was no statistically significant difference between the two groups(P>0.05).After treatment for six months,the rates of adverse reactions of radiotherapy group and combination treatment group were 46.7%(14/30)and 63.0%(17/27),respectively,there was no statistically significant difference between the two groups(P>0.05).The symptoms of patients with radiation injury significantly improved after symptomatic treatment.Conclusion The short-term efficacy of combination of 125 I seed brachytherapy and cetuximab is better than that of 125 I seed brachytherapy alone in patients with postoperation recurrent rectum cancer.
作者
汪建
张西坤
王斌
李山成
孙琳
孙文
郝亮
牛洪欣
Wang Jian;Zhang Xikun;Wang Bin;Li Shancheng;Sun Lin;Sun Wen;Hao Liang;Niu Hongxin(.Department of Minimally lnvasive Surgery,Affiliated Hospital of Shandong Academy of Medical Sciences,Jinan250031,China;Department of Gastrointestinal Surgery,First Hospital of Zibo City,255200,Shandong Province,China;Department of Minimally Invasive Surgery,Shandong Provincial Tumor Hospital Affiliated to Shandong University,Jinan250117,China)
出处
《中华消化杂志》
CAS
CSCD
北大核心
2019年第5期337-341,共5页
Chinese Journal of Digestion
基金
CSCO-默克雪兰诺肿瘤研究基金(Y-MX2016-001)CSCO-Merck Sherano Cancer Research Fund(Y-MX2016-001).
作者简介
通信作者:牛洪欣,Email:sdblache@126.com,电话:13789819676
